Charles Schwab (NYSE:SCHW) today reported record financial results for the first quarter of 2026, driven by unprecedented client engagement and robust organic growth across its core business segments.
JinkoSolar Holding (NYSE:JKS), one of the largest and most innovative solar module manufacturers in the world, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Manhattan Bridge Capital (NASDAQ:LOAN), a specialist in short-term "hard money" lending for real estate investors, reported a contraction in its financial results for the first quarter ended March 31, 2026.
Marsh McLennan (NYSE:MRSH), the world’s leading professional services firm in the areas of risk, strategy, and people, today reported financial results for the first quarter ended March 31, 2026.
The Travelers Companies (NYSE:TRV) reported a sharp increase in first-quarter profitability, as a relatively calm period for natural disasters allowed the insurer to capture the full benefits of higher premiums and rising investment yields.
U.S. Bancorp (NYSE:USB) reported a 14% increase in first-quarter profit, signaling a robust start to 2026 as the lender capitalized on a diversified revenue mix and disciplined cost management.
Eli Lilly (NYSE:LLY) reached a landmark milestone in its metabolic health pipeline on April 16, 2026, announcing positive topline results from the Phase 3 ACHIEVE-4 clinical trial.
Safe Harbor Financial (NASDAQ:SHFS), a leading financial technology platform for the cannabis and hemp industries, announced its financial results for the fourth quarter and full year ended December 31, 2025.
KeyCorp (NYSE:KEY) today announced its financial results for the first quarter ended March 31, 2026, showcasing significant growth across its core banking operations.
Transocean (NYSE:RIG) announced a significant contract award on April 16, 2026, for its ultra-deepwater drillship, the Deepwater Asgard.
Citizens Financial Group (NYSE:CFG) today reported a strong financial performance for the first quarter of 2026, characterized by double-digit growth in both profitability and per-share value.
Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral and liver diseases, announced on April 16, 2026, that it has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech.
